Name
Defining the Boundaries: Recent Rulings Shaping Drug Scope and IP Strategy
Description

This CLE examines recent judicial and regulatory developments shaping the scope of pharmaceutical patent protection, drug labeling, and regulatory exclusivity. The presentation addresses the U.S. Supreme Court’s decision in Hikma v. Amarin and its potential implications for pharmaceutical manufacturers. It will also examine the evolving scope of orphan drug exclusivity, including the Catalyst v. Becerra, the FDA’s response, and any recent legislative developments. Together, these developments highlight the interplay between patent law, FDA regulatory authority, and statutory interpretation, as well as practical considerations for attorneys advising pharmaceutical clients on patent protection, regulatory approval, and market-entry strategies.

Date & Time
Tuesday, December 15, 2026, 12:00 PM - 1:00 PM
Timezone
CST